MONOCLONAL ANTIBODY THERAPIES for Atopic Dermatitis: Where Are We Now in the Spectrum of Disease Management?

The Journal of Clinical and Aesthetic Dermatology

James Q. Del Rosso¹ 

[1] Dr. Del Rosso is Research Director of JDR Dermatology Research in Las Vegas, Nevada; is with Thomas Dermatology in Las Vegas, Nevada; and is Adjunct Clinical Professor (Dermatology) with Touro University Nevada in Henderson, Nevada.

关键词: Atopic dermatitis;    calcineurin inhibitors;    phosphodiesterase-4 inhibitors;    immunosuppressants;    interleukin-4;    interleukin-13;   

DOI  :  

学科分类：医学（综合）

来源: Matrix Medical Communications, LLC

【 摘 要 】

Atopic dermatitis (AD) is a chronic disorder that requires thorough patient education and a therapeutic management strategy designed to control flares, decrease recurrences, and reduce pruritus. In cases that cannot be controlled by proper skin care and barrier repair, topical therapy, and avoidance of triggers, systemic therapy is often required to control flares and maintain remission. It is important for clinicians to avoid becoming overly dependent on the intermittent use of systemic corticosteroid therapy to control flares, without incorporating other treatment options that might more optimally control AD over time. This article provides an overview of systemic therapies, including conventional oral therapy options and injectable biologic agents, that modulate the immune dysregulation in AD. Major emphasis is placed on the monoclonal antibodies currently available (e.g., dupilumab) for the treatment of AD, as well as those in latter stages of development, with a focus on agents targeting IL-4and/or IL-13.

【 授权许可】

Unknown